secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2026-07-13T12:05:22+00:00
Accession:  0001493152-26-032938
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 3.02, 3.03, 5.01, 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma to combine with GH Power; MTNB holders get 9% of combined co; sells Nano to Azurity
--------------------------------------------------------------------------------

- Business Combination Agreement with GH Power: MTNB shareholders receive 0.1 Pubco share per MTNB share; GH Power holders get ~91% of combined entity.
- Stock Purchase Agreement: Matinas Nano sold to Azurity for up to $21.5M cash ($4M upfront, $17.5M milestones) plus mid-single-digit royalty on MAT2203.
- Series D PIPE closed: $575,000 gross proceeds from sale of convertible preferred stock and warrants; requires stockholder approval for conversion shares.
- Post-closing board: 5 directors (1 from MTNB, 4 from GH Power); CEO and CFO expected from GH Power; lock-up 180 days for insiders.
- Termination fees: $1M payable by MTNB to GH Power if MTNB terminates for superior offer; $1M payable by GH Power to MTNB if GH Power terminates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226032938/0001493152-26-032938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226032938/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer